|Bid||0.00 x 0|
|Ask||119.00 x 100|
|Day's range||88.15 - 93.57|
|52-week range||28.35 - 136.90|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2018 - 5 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||133.44|
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Puma Biotechnology, Inc. , a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market® that meet NBI’s eligibility criteria.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the European Medicines Agency has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical aspects of the Marketing Authorization Application for neratinib at a meeting to be held on January 11, 2018.
Daiichi Sankyo Company, Limited and Puma Biotechnology, Inc. have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER tyrosine kinase inhibitor neratinib in HER2-mutated or HER2-positive solid tumors.
SAN DIEGO, Dec. 12, 2017-- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of shares against Puma Biotechnology Inc over alleged violations of Securities Laws. ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent , which were being opposed by Hexal AG.
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
Puma Biotechnology, Inc. , a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the 2017 San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
NEW YORK, Dec. 04, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
- Specialised Therapeutics Asia to make NERLYNX® (neratinib) available in Australia, New Zealand and South-East Asia for women with early-stage, HER2+ breast cancer following exclusive license agreement ...
Puma Biotechnology, Inc. , a biopharmaceutical company, and Specialised Therapeutics Asia, an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East Asia, have entered into an exclusive agreement under which Specialised Therapeutics will commercialize NERLYNX® throughout South East Asia, beginning with Australia, Singapore, Malaysia, Brunei ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma’s drug neratinib in patients with early stage HER2-positive breast cancer in the journal The Lancet Oncology.
Puma crashed after sales of its breast cancer drug crushed views but failed to live up to more bullish expectations.
The Los Angeles-based company said it had a loss of $2.07 per share. Losses, adjusted for stock option expense, were $1.36 per share. The results exceeded Wall Street expectations. The average estimate ...
Shares of Puma Biotechnology Inc. fell more than 8% late Thursday after the biotech company reported an adjusted third-quarter loss in line with expectations, and sales that were above Wall Street forecasts. ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30, 2017. Unless otherwise stated, all comparisons are for the third quarter and nine months of 2017 compared to the third quarter and nine months of 2016.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company, including recent developments, at 11:00 a.m.
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.